SAN FRANCISCO, March 19, 2020 /PRNewswire/ — Data and analytics platform Premise Data is offering a live dashboard displaying the findings of its ongoing global impact survey to assess the potential economic impact of Coronavirus (COVID-19). The survey assesses people’s sentiments about the virus and highlights behavioral changes, behaviors that are often seen as economic indicators. The survey will run for the foreseeable future.
Responses thus far come from 101,006 contributors in 69 countries, including the U.S. A public dashboard can be viewed here.
Highlights* from the survey include:
*As of March 19, 2020 at 8:52 a.m. PST
“Our growing network offers real-time insight into how this is changing lives,” said Premise Data CEO Maury Blackman. “We’re actively monitoring the behavioral changes that impact the economy and can report on them immediately.”
Premise works on a range of projects around the globe. For more, visit Premise.com.
About Premise:
Premise helps customers unlock a world of ground-level data. By combining the power of a global network of on-the-ground Contributors with industry-leading data science and machine learning, Premise empowers decision makers with the high-quality, trustworthy data they need. Premise is headquartered in San Francisco, with offices in Washington, D.C., and Seattle. Find more information at www.premise.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/premise-data-launches-live-dashboard-showing-real-time-sentiments-from-its-global-network-data-focused-on-coronavirus-covid-19-301027068.html
SOURCE Premise Data
MIAMI, FLORIDA / ACCESS Newswire / December 7, 2025 / MSP Recovery, Inc. (NASDAQ:MSPR) (the…
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…
Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92%…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab…